With the deal, Immedica will add ZTALMY (ganaxalone) oral suspension, CV, to its portfolio. A neuroactive steroid gamma-aminobutyric acid (GABA)-A receptor positive modulator, ZTALMY has been approved by the US Food and Drug Administration (FDA) in March 2022 for the treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients two years of age and older.

The acquisition is expected to accelerate Immedica’s growth into the North American market, providing an immediate revenue-generating rare disease product and an experienced commercial team.

“By adding ZTALMY to our portfolio, we significantly strengthen our capabilities and expand our presence in the United States, marking a new chapter in our mission to deliver impactful therapies for underserved patient populations,” said Anders Edvell, CEO of Immedica.

Scott Braunstein, chairman and CEO of Marinus, added: “I am proud of the dedication and passion of our team at Marinus, which allowed us to deliver the first and only FDA-approved treatment for seizures associated with CDKL5 deficiency disorder in patients two years of age and older.”

The closing of the transaction, which is subject to customary conditions, is expected to close in the first quarter of 2025.